Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that arise from neuroendocrine cells distributed throughout the body. These tumors can manifest in various organs, including the gastrointestinal tract, pancreas, lungs, and other sites where neuroendocrine cells are present. NETs are characterized by their ability to secrete bioactive substances such as hormones, neurotransmitters, or neuropeptides, which can lead to a wide range of clinical symptoms and complications.
Despite their relatively low incidence compared to other malignancies, the diagnosis and management of NETs present significant challenges due to their diverse clinical presentations, variable biological behavior, and complex molecular characteristics.
The etiology of NETs remains poorly understood, although several genetic, environmental, and hormonal factors have been implicated in their development. In recent years, advances in molecular biology and genetic sequencing techniques have provided valuable insights into the pathogenesis of NETs, revealing alterations in key signaling pathways such as the PI3K-AKT-mTOR pathway, the WNT signaling pathway, and the Notch signaling pathway. Additionally, germline mutations in genes such as MEN1, RET, VHL, and NF1 have been identified in familial forms of NETs, underscoring the genetic heterogeneity of these tumors.
Clinically, NETs can be categorized based on their site of origin, histological features, and functional status. The World Health Organization (WHO) classification system stratifies NETs into well-differentiated tumors (typical and atypical carcinoids) and poorly differentiated carcinomas (small cell and large cell neuroendocrine carcinomas), with grading based on mitotic rate and Ki-67 index. Functional NETs, which account for approximately 30% of cases, secrete hormones or bioactive substances that give rise to specific clinical syndromes such as carcinoid syndrome, insulinoma syndrome, gastrinoma syndrome, and others, depending on the type of hormone produced and the organ involved.
The clinical presentation of NETs varies widely depending on the tumor’s location, size, functional status, and metastatic spread. Patients with gastrointestinal NETs may present with abdominal pain, gastrointestinal bleeding, diarrhea, or bowel obstruction, while those with pancreatic NETs may experience abdominal discomfort, jaundice, or symptoms related to hormone hypersecretion. The diagnosis of NETs often requires a multidisciplinary approach, incorporating clinical, radiological, histological, and biochemical assessments. Imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and somatostatin receptor scintigraphy (SRS) play a crucial role in localizing primary tumors and detecting metastatic spread.
Histopathological examination of biopsy specimens remains the gold standard for diagnosing NETs and determining their grade and differentiation status. Immunohistochemical staining for neuroendocrine markers such as chromogranin A, synaptophysin, and neuron-specific enolase can aid in confirming the diagnosis and subclassifying NETs according to their histological features.
In addition to conventional histopathology, molecular profiling of NETs has emerged as a promising tool for risk stratification, prognostication, and guiding targeted therapies. Genetic testing for somatic mutations and germline variants can identify actionable targets and inform personalized treatment strategies, particularly in advanced or metastatic disease settings.
The management of NETs requires a tailored approach based on the tumor’s site, stage, grade, and functional status, as well as the patient’s overall health and preferences. For localized, well-differentiated NETs, surgical resection remains the cornerstone of treatment, aiming to achieve complete tumor removal and preserve organ function whenever feasible. In cases of unresectable or metastatic disease, a combination of systemic therapies including somatostatin analogs, targeted agents, peptide receptor radionuclide therapy (PRRT), and chemotherapy may be employed to control tumor growth, alleviate symptoms, and improve quality of life.
Somatostatin analogs such as octreotide and lanreotide are commonly used as first-line therapy for symptomatic control in patients with functional NETs, owing to their ability to inhibit hormone secretion and slow tumor progression. Targeted therapies directed against specific molecular targets such as the mammalian target of rapamycin (mTOR) pathway (e.g., everolimus) and the vascular endothelial growth factor (VEGF) pathway (e.g., sunitinib) have demonstrated efficacy in advanced NETs, particularly pancreatic NETs, by inhibiting angiogenesis and tumor cell proliferation. Peptide receptor radionuclide therapy (PRRT) utilizing radiolabeled somatostatin analogs such as ^177Lu-DOTATATE has shown promising results in patients with metastatic NETs expressing somatostatin receptors, offering a targeted approach to deliver radiation therapy directly to tumor cells while minimizing systemic toxicity.
In recent years, the advent of immunotherapy and immune checkpoint inhibitors has sparked interest in exploring their potential role in the treatment of NETs, particularly in the context of well-differentiated tumors with high tumor mutational burden or microsatellite instability. Clinical trials evaluating the efficacy of immune checkpoint inhibitors alone or in combination with other therapeutic modalities are underway, with the aim of harnessing the patient’s immune system to mount an anti-tumor response and improve outcomes in this challenging disease.
Despite advances in diagnostic techniques and therapeutic options, the prognosis of NETs remains highly variable and largely dependent on the tumor’s stage, grade, functional status, and biological behavior. While indolent, well-differentiated NETs confined to the primary site carry a favorable prognosis with long-term survival, aggressive, poorly differentiated carcinomas with distant metastases are associated with a dismal prognosis and limited treatment options.
Ongoing research efforts aimed at unraveling the molecular mechanisms underlying NETs, identifying novel therapeutic targets, and developing more effective treatment strategies hold promise for improving outcomes and quality of life for patients affected by this rare and complex malignancy.
